Horizon Pharma (HZNP) Rating Increased to Hold at Zacks Investment Research - Fairfield Current
Horizon Pharma (HZNP) Rating Increased to Hold at Zacks Investment Research Fairfield Current
Horizon Pharma (NASDAQ:HZNP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.
Comments
Post a Comment